Tags

Type your tag names separated by a space and hit enter

Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women.
Climacteric 2007; 10(6):500-7C

Abstract

OBJECTIVE

To compare the effects of raloxifene and soy phytoestrogens on endothelial function in healthy, postmenopausal women.

DESIGN

Randomized, double-blind, placebo-controlled, cross-over trial. Subjects (n = 22; mean age 58.5 years) underwent endothelial function testing at baseline and following 6 weeks of daily raloxifene 60 mg, soy phytoestrogens 55 mg, and placebo in random sequence with intervening 6-week wash-out periods. Endothelial function was assessed as flow-mediated vasodilatation (FMD) of the brachial artery using high-resolution ultrasound; digital flux was measured with laser Doppler velocimetry.

RESULTS

Baseline (pretreatment) FMD was almost within normal range at 9.6% (+/-6.4). FMD did not change from baseline within any treatment group, and no between-group differences were detected. FMD values following treatment with raloxifene, soy, and placebo were 10.3% (+/-12.3), 8.3% (+/-7.7), and 9.5% (+/-4.4), respectively. Area under curve ratios showed no treatment differences for digital velocimetry.

CONCLUSIONS

In this study, neither raloxifene nor soy enhanced endothelial function in postmenopausal women. However, the cohort had relatively normal endothelial function at baseline. Further study is required to determine if particular subgroups of postmenopausal women derive vascular benefit from the use of selective estrogen receptor modulators or soy phytoestrogens.

Authors+Show Affiliations

Yale Prevention Research Center, Derby, CT 06418, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18049943

Citation

Katz, D L., et al. "Raloxifene, Soy Phytoestrogens and Endothelial Function in Postmenopausal Women." Climacteric : the Journal of the International Menopause Society, vol. 10, no. 6, 2007, pp. 500-7.
Katz DL, Evans MA, Njike VY, et al. Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women. Climacteric. 2007;10(6):500-7.
Katz, D. L., Evans, M. A., Njike, V. Y., Hoxley, M. L., Nawaz, H., Comerford, B. P., & Sarrel, P. M. (2007). Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women. Climacteric : the Journal of the International Menopause Society, 10(6), pp. 500-7.
Katz DL, et al. Raloxifene, Soy Phytoestrogens and Endothelial Function in Postmenopausal Women. Climacteric. 2007;10(6):500-7. PubMed PMID: 18049943.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women. AU - Katz,D L, AU - Evans,M A, AU - Njike,V Yanchou, AU - Hoxley,M L, AU - Nawaz,H, AU - Comerford,B P, AU - Sarrel,P M, PY - 2007/12/1/pubmed PY - 2008/3/15/medline PY - 2007/12/1/entrez SP - 500 EP - 7 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 10 IS - 6 N2 - OBJECTIVE: To compare the effects of raloxifene and soy phytoestrogens on endothelial function in healthy, postmenopausal women. DESIGN: Randomized, double-blind, placebo-controlled, cross-over trial. Subjects (n = 22; mean age 58.5 years) underwent endothelial function testing at baseline and following 6 weeks of daily raloxifene 60 mg, soy phytoestrogens 55 mg, and placebo in random sequence with intervening 6-week wash-out periods. Endothelial function was assessed as flow-mediated vasodilatation (FMD) of the brachial artery using high-resolution ultrasound; digital flux was measured with laser Doppler velocimetry. RESULTS: Baseline (pretreatment) FMD was almost within normal range at 9.6% (+/-6.4). FMD did not change from baseline within any treatment group, and no between-group differences were detected. FMD values following treatment with raloxifene, soy, and placebo were 10.3% (+/-12.3), 8.3% (+/-7.7), and 9.5% (+/-4.4), respectively. Area under curve ratios showed no treatment differences for digital velocimetry. CONCLUSIONS: In this study, neither raloxifene nor soy enhanced endothelial function in postmenopausal women. However, the cohort had relatively normal endothelial function at baseline. Further study is required to determine if particular subgroups of postmenopausal women derive vascular benefit from the use of selective estrogen receptor modulators or soy phytoestrogens. SN - 1369-7137 UR - https://www.unboundmedicine.com/medline/citation/18049943/Raloxifene_soy_phytoestrogens_and_endothelial_function_in_postmenopausal_women_ L2 - http://www.tandfonline.com/doi/full/10.1080/13697130701750123 DB - PRIME DP - Unbound Medicine ER -